First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Grifols: the story is balanced — Plasma collection volumes and donor center productivity (liters collected per center per month) - directly impacts raw…
★ Analysts see FY2027 revenue reaching $8.1B — +6.0% growth in a single year.
What Moves the Stock
1Plasma collection volumes and donor center productivity (liters collected per center per month) - directly impacts raw material availability and revenue potential
2Immunoglobulin pricing dynamics in US and European markets - IVIG represents 40-45% of bioscience revenue with pricing pressure from payers and biosimilar threats
3Regulatory approvals for new indications or manufacturing capacity expansions - FDA approval cycles and facility certifications unlock revenue growth
4US dollar strength versus euro - approximately 60% of revenue is dollar-denominated while significant costs are euro-based, creating FX translation sensitivity
5Debt refinancing and deleveraging progress - company emerged from accounting controversy in 2024-2025 requiring balance sheet repair
6Bioscience division (~75% of revenue): Plasma-derived protein therapies including immunoglobulins (IVIG/SCIG), albumin, and alpha-1 antitrypsin for chronic conditions
7Diagnostic division (~15% of revenue): Blood typing, infectious disease screening, and donor management systems for transfusion medicine
8Bio Supplies division (~10% of revenue): Raw materials and instruments for clinical laboratories and pharmaceutical manufacturing
value - Stock trades at 1.0x sales and 0.1x book value, reflecting deep distress discount from 2024 accounting controversy.
Rising interest rates create moderate headwinds through two channels: (1) Higher financing costs on the company's €6-7B debt load…
Watch on earnings: US unemployment rate (UNRATE) - inverse correlation with plasma donor availability and acquisition costs, Euro/dollar exchange rate (inverse of DEXCHUS as proxy) - 60% revenue in USD, significant euro costs create 15-20% earnings sensitivity to 10% FX moves, High-yield credit spreads (BAMLH0A0HYM2) - proxy for refinancing conditions and credit market access given elevated leverage.
One Sentence Summary:
Grifols: the story is balanced — plasma collection volumes and donor center productivity (liters collected per center per month) - directly impacts raw material availability.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.